ROCKVILLE, Md. and BASEL, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, and BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, today announced the signing of a collaboration agreement for the deployment and use of the Unyvero platform in BioVersys’ upcoming Phase II clinical trial of novel drug candidate BV100.
The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, signed a €20 million venture debt transaction. The financing supports the company’s research and development of a diverse pipeline of drugs that address antimicrobial resistance (AMR). AMR has resulted in the majority of antimicrobial therapies becoming obsolete, potentially resulting in a bacterial pandemic.
BASEL, Switzerland, November 18, 2020 / B3C newswire / -- BioVersys has reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, today announced that the first healthy volunteers have received BV100 in a Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of BV100 in healthy human volunteers through Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies.
Switzerland based Bioversys has recently reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, today announced that the first healthy volunteers have received BV100 in Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of BV100 in healthy human volunteers through Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies.
 BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candidates into first in human clinical trials and has also strengthened its board with the appointment of Dr. Eduard Holdener.